Professor of Medicine, M.D. Anderson Cancer Center Adjunct Professor of Medicine and Cell Biology, Baylor College of Medicine
Endocrinology
Dr. Robert F. Gagel, MD
|
|
Give Review
Robert F. Gagel works in the field of Endocrinology. He graduated from Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He received awards:"America's Top Doctors for Cancer", "Super Doctor", "America's Top Doctors" and "Top Doctors:SE Texas". Robert Gagel is a published doctor and has 57 publications published. The lastest was: 'Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience.' Robert Gagel is registered with Medicare and accepts Medicare payments.
Publications
- Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience.
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary T...
- A Novel Dual Kinase Function of the RET Proto-oncogene Negatively Regulates Activating Transcription Factor 4-Mediated Apoptosis.
- Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations.
- The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2.
- Deletion of the Gene Encoding Calcitonin and CGRP? Does Not Affect the Outcome of Severe Infection in Mice.
- The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring.
- Activation of G-Protein-Coupled Receptors and Thyroid Malignant Tumors: The Jury is Still Out.
- Vandetanib in patients with locally advanced or metastatic medullary Thyroid cancer: a randomized, double-blind phase III trial.
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer.
- Epidemiology and risk factors for osteonecrosis of the jaw in Cancer patients.
- The evolving field of tyrosine kinase inhibitors in the treatment of Endocrine tumors.
- Cancer therapies and bone health.
- Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary Thyroid cancer.
- Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
- Targeted therapy for endocrine cancer: the medullary Thyroid carcinoma paradigm.
- The calcitonin/calcitonin gene related peptide-alpha gene is not required for 1alpha,25-dihydroxyVitamin D3-mediated suppression of experimental autoimmune encephalomy...
- NCCN Task Force Report: Bone Health in Cancer Care.
- Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary Thyroid cancer.
- Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: iden...
- High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary Thyroid carcinoma.
- Four patients with cutaneous metastases from medullary Thyroid cancer.
- Frequency and risk factors associated with osteonecrosis of the jaw in Cancer patients treated with intravenous bisphosphonates.
- Management of medullary Thyroid carcinoma.
- Recent advances in Thyroid cancer.
- Recent advances in Thyroid cancer. In brief.
- Bone loss in patients with breast or prostate Cancer.
- ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer Syndromes.
- Calcitonin plays a critical role in regulating skeletal mineral Metabolism during lactation.
- Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary Syndromes?
- Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
- Management of pancreatic endocrine tumors in multiple endocrine neoplasia Type 1.
- Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of Osteoporosis.
- Glucose homeostasis and safety in patients with Acromegaly converted from long-acting octreotide to pegvisomant.
- Primary hyperparaThyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma.
- RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary Thyroid cancer and associated endocrine tumors.
- Osteoporosis in breast and prostate cancer survivors.
- Surgical treatment of hyperparaThyroidism in patients with multiple endocrine neoplasia type 1.
- Decreased bone formation and Osteopenia in mice lacking alpha-calcitonin gene-related peptide.
- Pheochromocytoma and medullary Thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.
- ParaThyroid carcinoma: a 22-year experience.
- Ablation of calcitonin/calcitonin gene-related peptide-alpha impairs fetal magnesium but not Calcium homeostasis.
- A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary Thyroid carcinoma.
- Surgical management of hereditary pheochromocytoma.
- Potential role for intraoperative gamma probe identification of normal paraThyroid glands.
- Medullary Thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients.
- The role of genetics in the surgical management of familial endocrinopathy Syndromes.
- Lessons learned from the management of a rare genetic Cancer.
- Multiple endocrine neoplasia Type 2: evaluation of the genoType-phenoType relationship.
- Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary Thyroid carcinoma.
- Increased bone mass is an unexpected phenoType associated with deletion of the calcitonin gene.
- Improving the yield of preoperative paraThyroid localization: technetium Tc 99m-sestamibi imaging after Thyroid suppression.
- GenoType-phenoType analysis in multiple endocrine neoplasia Type 1.
- When "The 7-Year Itch" is indicative of an Endocrine malignant condition.
- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
- A miRNA signature associated with human metastatic medullary Thyroid carcinoma.
Schools
Ohio State University College of Medicine
Tufts New England Med Center
Harvard Med School
Tufts New Eng Med Center
Conditions Treated
- Abnormal Thyroid
- Acromegaly and Gigantism
- Calcium Metabolism Disorders
- Craniopharyngioma
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- America's Top Doctors for Cancer
- Super Doctor
- America's Top Doctors
- Top Doctors:SE Texas
Education
-
Harvard Medical School -
Tufts Medical Center -
The Ohio State University College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1265537468 | |
| NPPES Provider LastName | GAGEL | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 192.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265537468 |
| Last Name Of The Provider | GAGEL |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Erica E. Hightower, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeena M. Varghese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marco Marcelli, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jose F. Zavaleta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Perry E. Bickel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sonali N. Thosani, MD
This Doctor is OpenDoctor Recommended.
|